Pal SK - Search Results

1

Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.

Ali SM, Stephens PJ, Miller VA, Ross JS, Pal SK. Ali SM, et al. Among authors: pal sk. Eur Urol. 2015 Aug;68(2):341-3. doi: 10.1016/j.eururo.2015.03.002. Epub 2015 Mar 18. Eur Urol. 2015. PMID: 25796537 No abstract available.

2

The role of targeting mammalian target of rapamycin in lung cancer.

Pal SK, Figlin RA, Reckamp KL. Pal SK, et al. Clin Lung Cancer. 2008 Nov;9(6):340-5. doi: 10.3816/CLC.2008.n.049. Clin Lung Cancer. 2008. PMID: 19073516 Review.

3

Renal cell carcinoma therapy in 2010: many options with little comparative data.

Pal SK, Figlin RA. Pal SK, et al. Clin Adv Hematol Oncol. 2010 Mar;8(3):191-200. Clin Adv Hematol Oncol. 2010. PMID: 20400934 Review.

4

Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling.

Pal SK, Reckamp KL. Pal SK, et al. J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S487-9. doi: 10.1097/01.JTO.0000391378.17179.8f. J Thorac Oncol. 2010. PMID: 21102251 Free PMC article. No abstract available.

5

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.

Pal SK, Figlin RA. Pal SK, et al. Target Oncol. 2011 Mar;6(1):5-16. doi: 10.1007/s11523-011-0172-y. Epub 2011 Apr 12. Target Oncol. 2011. PMID: 21484496 Free PMC article. Review.

6

Systemic therapies for metastatic renal cell carcinoma in older adults.

Pal SK, Vanderwalde A, Hurria A, Figlin RA. Pal SK, et al. Drugs Aging. 2011 Aug 1;28(8):635-49. doi: 10.2165/11592880-000000000-00000. Drugs Aging. 2011. PMID: 21812499 Free PMC article. Review.

7

Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS.

Pal SK, Vogelzang NJ. Pal SK, et al. Clin Genitourin Cancer. 2011 Sep;9(1):3-5. doi: 10.1016/j.clgc.2011.06.003. Epub 2011 Aug 3. Clin Genitourin Cancer. 2011. PMID: 21816688 No abstract available.

8

Role of surgery for locally advanced and metastatic renal cell carcinoma.

Torrey R, Spiess PE, Pal SK, Josephson D. Torrey R, et al. Among authors: pal sk. J Natl Compr Canc Netw. 2011 Sep 1;9(9):985-93. doi: 10.6004/jnccn.2011.0083. J Natl Compr Canc Netw. 2011. PMID: 21917623 Review.

9

Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.

Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn DI. Pal SK, et al. Mol Cancer Ther. 2012 Mar;11(3):526-37. doi: 10.1158/1535-7163.MCT-11-0806. Epub 2012 Feb 17. Mol Cancer Ther. 2012. PMID: 22351744 Free PMC article. Review.

10

Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.

Pal SK, Jones JO, Carmichael C, Saikia J, Hsu J, Liu X, Figlin RA, Twardowski P, Lau C. Pal SK, et al. Urol Oncol. 2013 Nov;31(8):1826-31. doi: 10.1016/j.urolonc.2012.04.007. Epub 2012 May 17. Urol Oncol. 2013. PMID: 22608544 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,146 results

Search Page

Filters